Clinic to Bench and Bench to Clinic: Developing Safer Biologics

Gerald Clarke
Posted: 12/03/2013

On the 13thof March 2006 six men entered Northwick Park to participate in a first-in-man study. At 8:00 they began receiving an infusion of TGN1412 a humanised monoclonal antibody targeting the CD28 receptor. The antibody therapy was intended to be a therapy for B cell chronic lymphocytic leukemia (B-CLL). Within minutes, the patients began reporting headaches, fever and pain. Soon, this has worsened to severe pain and swelling resulting in the men being moved to intensive care. Many of them stayed for weeks and one patient did not leave hospital for months.

Gerald Clarke
Posted: 12/03/2013